{"id":69244,"date":"2026-07-02T15:10:17","date_gmt":"2026-07-02T07:10:17","guid":{"rendered":"https:\/\/flcube.com\/?p=69244"},"modified":"2026-07-02T15:10:18","modified_gmt":"2026-07-02T07:10:18","slug":"transthera-advances-phase-ii-trial-of-selective-btk-inhibitor-tt-01488-with-anti-cd20-antibodies-for-mantle-cell-lymphoma-novel-non-covalent-approach-shows-enhanced-safety-profile","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69244","title":{"rendered":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TransThera (Nanjing) Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2617:HKG\">HKG: 2617<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>Phase II clinical trial<\/strong> of <strong>TT-01488 tablets<\/strong> in combination with <strong>anti-CD20 monoclonal antibody-containing regimens<\/strong> for the treatment of <strong>mantle cell lymphoma (MCL)<\/strong>. The novel <strong>non-covalent BTK inhibitor<\/strong> demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-framework\" class=\"wp-block-heading\">Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Multicenter, open-label, dose-exploration and expansion<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>TT-01488 + anti-CD20 monoclonal antibody regimens<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Mantle cell lymphoma (MCL)<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety, tolerability, and efficacy evaluation<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Phase I completed; Phase II authorized<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-differentiating-characteristics\" class=\"wp-block-heading\">Drug Profile &amp; Differentiating Characteristics<\/h2>\n\n\n\n<h3 id=\"h-tt-01488-next-generation-btk-inhibitor\" class=\"wp-block-heading\">TT-01488 \u2013 Next-Generation BTK Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Novel non-covalent Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Independently developed by TransThera with full IP rights<\/li>\n\n\n\n<li><strong>Kinase Selectivity Profile:<\/strong><\/li>\n\n\n\n<li>Excellent target activity against BTK<\/li>\n\n\n\n<li>Low affinity for EGFR and Tec kinases<\/li>\n\n\n\n<li>Superior kinase selectivity reducing off-target effects<\/li>\n\n\n\n<li><strong>Safety Advantages:<\/strong><\/li>\n\n\n\n<li>Reduced risk of atrial fibrillation<\/li>\n\n\n\n<li>Decreased bleeding complications<\/li>\n\n\n\n<li>Better overall safety profile vs. covalent BTK inhibitors<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-preclinical-amp-clinical-evidence\" class=\"wp-block-heading\">Preclinical &amp; Clinical Evidence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Preclinical Data:<\/strong> Robust antitumor activity demonstrated in xenograft models of tumor lymphocytes<\/li>\n\n\n\n<li><strong>Phase I Results:<\/strong> <strong>70% objective response rate (ORR)<\/strong> in patients with non-blastoid MCL<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Synergistic effects anticipated when combined with CD20 monoclonal antibodies<\/li>\n\n\n\n<li><strong>Therapeutic Index:<\/strong> Enhanced efficacy-toxicity ratio suggests potential for improved patient outcomes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MCL Burden:<\/strong> Rare but aggressive B-cell lymphoma with poor prognosis; median survival 5-7 years<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) with significant toxicity limitations<\/li>\n\n\n\n<li><strong>Addressable Population:<\/strong> Estimated 3,000-5,000 MCL patients annually in China requiring second-line therapy<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> First non-covalent BTK inhibitor in advanced development for MCL in China<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Non-covalent approach addresses key safety concerns limiting current BTK inhibitor use<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Strengthens TransThera&#8217;s position in hematological malignancies beyond solid tumors<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> NMPA approval positions TT-01488 for potential accelerated approval based on Phase II data<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Combination approach leverages established anti-CD20 antibody market while differentiating through improved safety<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong Phase II data could attract global pharmaceutical partners for international development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development and competitive positioning. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive dynamics, and market adoption of novel BTK inhibitors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070100118_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070100118_c.\"><\/object><a id=\"wp-block-file--media-207a0ef9-7f91-4ce9-9387-c44334ffc22c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070100118_c.pdf\">2026070100118_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070100118_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-207a0ef9-7f91-4ce9-9387-c44334ffc22c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,4181,33,601],"class_list":["post-69244","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-2617","tag-tkis-egfr-vegf-btk-etc","tag-transthera-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China&#039;s National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69244\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile\" \/>\n<meta property=\"og:description\" content=\"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China&#039;s National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69244\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T07:10:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T07:10:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile\",\"datePublished\":\"2026-07-02T07:10:17+00:00\",\"dateModified\":\"2026-07-02T07:10:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 2617\",\"TKIs (EGFR VEGF BTK etc.)\",\"TransThera Sciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69244#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69244\",\"name\":\"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-02T07:10:17+00:00\",\"dateModified\":\"2026-07-02T07:10:18+00:00\",\"description\":\"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69244\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69244#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile - Insight, China&#039;s Pharmaceutical Industry","description":"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69244","og_locale":"en_US","og_type":"article","og_title":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile","og_description":"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.","og_url":"https:\/\/flcube.com\/?p=69244","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-02T07:10:17+00:00","article_modified_time":"2026-07-02T07:10:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69244#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69244"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile","datePublished":"2026-07-02T07:10:17+00:00","dateModified":"2026-07-02T07:10:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69244"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 2617","TKIs (EGFR VEGF BTK etc.)","TransThera Sciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69244#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69244","url":"https:\/\/flcube.com\/?p=69244","name":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-02T07:10:17+00:00","dateModified":"2026-07-02T07:10:18+00:00","description":"TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China's National Medical Products Administration (NMPA) has approved a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody-containing regimens for the treatment of mantle cell lymphoma (MCL). The novel non-covalent BTK inhibitor demonstrates superior kinase selectivity and reduced toxicities compared to existing covalent BTK inhibitors, with promising early clinical response rates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69244#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69244"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69244#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma \u2013 Novel Non-Covalent Approach Shows Enhanced Safety Profile"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69244"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69244\/revisions"}],"predecessor-version":[{"id":69246,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69244\/revisions\/69246"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}